早鸽—汇聚行业精英
  • 联系客服
  • 帮助中心
  • 投诉举报
  • 关注微信
400-006-1351
您的问题早鸽都有答案
3000+专业顾问
搜索
咨询

携带乙肝病毒抗原表位的重组嵌合蛋白及其制备制作方法

  • 专利名称
    携带乙肝病毒抗原表位的重组嵌合蛋白及其制备制作方法
  • 发明者
  • 公开日
  • 申请日期
  • 优先权日
  • 申请人
  • 文档编号
  • 关键字
  • 技术领域
    本发明涉及一种重组嵌合蛋白,尤其是一种以轮状病毒VP6蛋白为载体携带乙肝病毒抗原表位的重组嵌合蛋白及其制备,属于医学生物技术领域
  • 背景技术
  • 具体实施例方式
    实施例I
  • 专利详情
  • 全文pdf
  • 权力要求
  • 说明书
  • 法律状态
专利名称:携带乙肝病毒抗原表位的重组嵌合蛋白及其制备的制作方法轮状病毒(Rotavirus,简称RV)是婴幼儿腹泻的主要病原体。世界范围内每 年大约有60多万例RV感染患者死亡,其中80%发生在发展中国家。RV属呼肠病毒科(Meoviridae),轮状病毒属(Rotavirus)0 RV基因组由11个片段的双链RNA组成,分别编码6个结构蛋白(VP1-VP4, VP6和VP7)和6个非结构蛋白(NSP1-NSP5/NSP6)。根据RV组(亚组)抗原蛋白VP6的抗原性的不同,可将至今已发现的轮状病毒RV分为A G七个组,A组是婴幼儿腹泻的主要病原体。根据病毒蛋白编码框(ORF)核苷酸序列同源性差异,可将A组轮状病毒RV的12个蛋白(基因)分为不同的基因型。根据RV基因型分类标准,A组轮状病毒RV的结构蛋白VP6至少可分为16个基因型(11-116型)。VP6蛋白由第6基因片段编码,含397个氨基酸,分子量约为44. 8KDa。VP6蛋白是轮状病毒RV中含量最丰富的蛋白,约占病毒总蛋白量的51%。RV内壳中间层由260个致密的VP6蛋白三聚体共780个蛋白分子构成。VP6蛋白具有重要的生物学功能,是病毒基因组转录和病毒组装不可缺少的成分。VP6蛋白也具有重要的免疫学性质。近年进行的VP6蛋白免疫学研究表明,一些抗VP6蛋白的IgA单克隆抗体诸如7D9所产生的IgA具有保护作用,在SCID鼠中可清除其慢性RV病毒感染。一些研究表明VP6蛋白的抗病毒作用可能是通过IgA的分泌途径而阻碍了病毒的复制循环过程,或作为一种黏膜的分泌型IgAJf RV感染的上皮细胞排除,从而起到保护作用。研究发现VP6蛋白分子中至少存在两个Th细胞抗原表位和一个交叉反应的细胞毒性T淋巴细胞(CTL)表位。有研究表明在使用麦芽糖结合VP6蛋白对小鼠进行黏膜免疫后,IFN- Y被认为是⑶4+T细胞分泌的唯一有效的抗RV的细胞因子。众多的实验表明,经VP6蛋白免疫后,在动物体内确实能引起抗RV感染的作用。抗VP6蛋白单克隆抗体具有抑制病毒转录活性和保护小鼠免受病毒感染的作用。用重组表达的VP6蛋白免疫小鼠,也可诱导小鼠产生免疫保护作用。VP6蛋白可自我组装成病毒样颗粒(VLPs)。由于VLPs没有感染性,在研究细胞相互作用,开发诊断制剂和疫苗方面,具有更好的安全性。与单一分子的重组抗原相比,VLPs具有更好的免疫原性,可刺激机体产生体液和细胞免疫反应。由于VLPs具有高密度的呈递抗原表位,可产生很强的免疫反应,是许多疫苗研制中很有前景的材料。至今所有已用于人体的轮状病毒RV疫苗都是减毒活疫苗。1997年始用于人体的多价减毒重组活疫苗Rotashield因后来发现与肠套叠有关联而在使用一年后即停止使用。2006年和2008年分别获准在人群中使用的5价重组减毒活疫苗RotaTeq和单价重组减毒活疫苗Rotarix现也已发现有猪环状病毒DNA污染。Rotarix已在美国人群中停止使用,RotaTeq在人群中尚可正常使用。由于上述用于人类的RV疫苗存在肠套叠和其他病毒核酸污染等风险,且都存在只能降低RV感染引起的死亡率和重症腹泻,不能完全保护RV感染的不足,在Rotarix停用后,RV感染率似有所提高。乙肝病毒(HeptatitisB Virus,简称 HBV)属嗜肝DNA病毒科(Hepadnaviridae),是引起人类急慢性肝炎、肝硬化及肝癌的重要病原。我国现有慢性HBV感染者9300万人。至今已有的能够有效治疗乙肝的药物都存在副作用大的问题,因此,疫苗免疫仍然是主要的控制措施。乙肝难于治疗和预防的重要原因,是因为HBV基因组结构复杂,变异很大。根据HBV基因核苷酸(氨基酸)序列同源性差异,至今发现的HBV株至少可以分为10个基因型(基因型A-J)和数十个基因亚型。因此对HBV蛋白免疫学性质进行深入研究,改进疫苗免疫保护效果,仍有重要的理论意义和使用价值。研制重组抗原表位亚单位疫苗是一个重要的方向。HBV抗原表位在表面抗原蛋白PreSl,PreS2, S及核心蛋白C上均有分布,在尚无理想的治疗RV和HBV感染药物,以及RV和HBV疫苗尚不十分理想的今天,选择和鉴定这些蛋白上的抗原表位,研制更加安全有效的RV和HBV疫苗,特别是研制可同时保护RV/HBV感染的联合疫苗具有重要的经济和社会价值。
本发明的目的在于提供一种携带有乙肝病毒S82抗原表位的重组嵌合蛋白及制备,以用作RV/HBV重组嵌合疫苗及试剂。本发明的目的还在于提供一种携带有乙肝病毒C19抗原表位的重组嵌合蛋白及制备,以用作RV/HBV重组嵌合疫苗及试剂。本发明的目的又在于提供一种携带有乙肝病毒S125抗原表位的重组嵌合蛋白及制备,以用作RV/HBV重组嵌合疫苗及试剂。本发明的目的在于提供一种携带有乙肝病毒S2[8]抗原表位的重组嵌合蛋白及制备,以用作RV/HBV重组嵌合疫苗及试剂。本发明的目的在于提供一种携带有乙肝病毒SI [93]抗原表位的重组嵌合蛋白及制备,以用作RV/HBV重组嵌合疫苗及试剂。本发明的目的在于提供一种携带有乙肝病毒C117抗原表位的重组嵌合蛋白及制备,以用作RV/HBV重组嵌合疫苗及试剂。本发明的另一目的在于提供一种同时携带乙肝病毒382,(19,5125,52[8],51[93]和C117抗原表位的重组嵌合蛋白及制备,以用作RV/HBV重组嵌合疫苗及试剂。本发明提供的携带有乙肝病毒S82抗原表位的重组嵌合蛋白的氨基酸序列为 Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp Lys He ValGlu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu He Gln Gln Phe Asn Gln Met He IleThr Met Asn Gly Asn Glu Phe Gln Thr Gly Gly He Gly Asn Leu Pro Thr Arg Asn TrpSer Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val GluThr Ala Arg Asn Thr He Asp Tyr Phe Val Asp Phe Val Asp Asn Val Cys Met Asp GluMet Val Arg Glu Ser Gln Arg Asn Gly He Ala Pro Gln Ser Glu Ser Leu Arg Lys Leu Ser Gly He Lys Phe Lys Arg He Asn Phe Asp Asn Ser Ser Glu Tyr He Glu Asn TrpAsn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro Asn He Phe ProTyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Ala His Glu Leu Phe Leu Phe lieLeu Leu Leu Cys Leu Glu Leu Met Gly Thr Met Trp Leu Asn Ala Gly Ser Glu lie GlnVal Ala Gly Phe Asp Tyr Ser Asn He Gln Gln Phe Glu His lie Val Gln Leu Arg ArgVal Leu Thr Thr Ala Thr He Thr Leu Leu Pro Asp Ala Glu Arg Phe Ser Phe Pro ArgVal He Asn Ser Ala Asp Gly Thr Thr Trp Tyr Phe Asn Pro Val lie Leu Arg Pro AsnAsn Val Glu Val Glu Phe Leu Leu Asn Gly Gln He lie Asn Thr Tyr Gln Ala Pro ArgPhe Gly Thr He Val Ala Arg Asn Phe Asp Thr He Arg Leu Ser Phe Gln Leu Met ArgPro Arg Thr Pro Ser Val Ala Ala Leu Glu His His Ala Thr Val Gly Leu Thr Leu ArgHe Glu Ser Ala He Cys Glu Ser Val Leu Ala Asp Ala Ser Glu Thr Met Leu Ala AsnVal Thr Ser Val Arg Gln Glu Tyr Ala He Pro Val Gly Pro Val Phe Pro Pro Gly MetAsn Trp Thr Asp Leu He Thr Asn Tyr Ser Pro Ser Arg Glu Asp Asn Leu Gln Arg ValPhe Thr Val Ala Ser lie Arg Ser Met Leu Val Lys0所述抗原表位S82的氨基酸序列为Phe Leu Phe He Leu Leu Leu Cys Leu。本发明提供的携带有乙肝病毒C19抗原表位的重组嵌合蛋白的氨基酸序列为 Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp Lys He ValGlu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu He Gln Gln Phe Asn Gln Met He IleThr Met Asn Gly Asn Glu Phe Gln Thr Gly Gly He Gly Asn Leu Pro Thr Arg Asn TrpSer Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val GluThr Ala Arg Asn Thr He Asp Tyr Phe Val Asp Phe Val Asp Asn Val Cys Met Asp GluMet Val Arg Glu Ser Gln Arg Asn Gly He Ala Pro Gln Ser Glu Ser Leu Arg Lys LeuSer Gly He Lys Phe Lys Arg He Asn Phe Asp Asn Ser Ser Glu Tyr He Glu Asn TrpAsn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro Asn He Phe ProTyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Ala His Glu Leu Met Gly Thr MetTrp Leu Asn Ala Gly Ser Glu He Gln Val Ala Gly Phe Asp Tyr Ser Asn Ser Phe LeuPro Ser Asp Phe Phe Pro Ser Val Arg Asp Ser Asn He Gln Gln Phe Glu His He ValGln Leu Arg Arg Val Leu Thr Thr Ala Thr He Thr Leu Leu Pro Asp Ala Glu Arg PheSer Phe Pro Arg Val He Asn Ser Ala Asp Gly Thr Thr Trp Tyr Phe Asn Pro Val IleLeu Arg Pro Asn Asn Val Glu Val Glu Phe Leu Leu Asn Gly Gln Ile He Asn Thr TyrGln Ala Pro Arg Phe Gly Thr He Val Ala Arg Asn Phe Asp Thr He Arg Leu Ser PheGln Leu Met Arg Pro Arg Thr Pro Ser Val Ala Ala Leu Glu His His Ala Thr Val GlyLeu Thr Leu Arg He Glu Ser Ala He Cys Glu Ser Val Leu Ala Asp Ala Ser Glu ThrMet Leu Ala Asn Val Thr Ser Val Arg Gln Glu Tyr Ala He Pro Val Gly Pro Val PhePro Pro Gly Met Asn Trp Thr Asp Leu He Thr Asn Tyr Ser Pro Ser Arg Glu Asp AsnLeu Gln Arg Val Phe Thr Val Ala Ser He Arg Ser Met Leu Val Lys0所述抗原表位C19 的氨基酸序列为Ser Phe Leu Pro Ser Asp Phe Phe Pro SerVal Arg Asp。本发明提供的携带有乙肝病毒S125抗原表位的重组嵌合蛋白的氨基酸序列为 Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp Lys He ValGlu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu He Gln Gln Phe Asn Gln Met He IleThr Met Asn Gly Asn Glu Phe Gln Thr Gly Gly lie Gly Asn Leu Pro Thr Arg Asn TrpSer Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val GluThr Ala Arg Asn Thr He Asp Tyr Phe Val Asp Phe Val Asp Asn Val Cys Met Asp GluMet Val Arg Glu Ser Gln Arg Asn Gly He Ala Pro Gln Ser Glu Ser Leu Arg Lys LeuSer Gly He Lys Phe Lys Arg He Asn Phe Asp Asn Ser Ser Glu Tyr lie Glu Asn TrpAsn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro Asn lie Phe ProTyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Ala His Glu Leu Met Gly Thr MetTrp Leu Asn Ala Gly Ser Glu He Gln Val Ala Gly Phe Asp Tyr Ser Asn lie Gln GlnPhe Glu His He Val Gln Leu Arg Arg Val Leu Thr Thr Ala Thr lie Thr Leu Leu ProAsp Ala Glu Arg Phe Ser Phe Pro Arg Val He Asn Ser Ala Asp Gly Thr Thr Pro AlaGln Gly Asn Ser Met Phe Pro Ser Cys Cys Cys Thr Lys Pro Thr Asp Gly Thr Thr TrpTyr Phe Asn Pro Val He Leu Arg Pro Asn Asn Val Glu Val Glu Phe Leu Leu Asn GlyGln He He Asn Thr Tyr Gln Ala Pro Arg Phe Gly Thr lie Val Ala Arg Asn Phe AspThr He Arg Leu Ser Phe Gln Leu Met Arg Pro Arg Thr Pro Ser Val Ala Ala Leu GluHis His Ala Thr Val Gly Leu Thr Leu Arg He Glu Ser Ala lie Cys Glu Ser Val LeuAla Asp Ala Ser Glu Thr Met Leu Ala Asn Val Thr Ser Val Arg Gln Glu Tyr Ala liePro Val Gly Pro Val Phe Pro Pro Gly Met Asn Trp Thr Asp Leu lie Thr Asn Tyr SerPro Ser Arg Glu Asp Asn Leu Gln Arg Val Phe Thr Val Ala Ser lie Arg Ser Met LeuVal Lys0所述抗原表位S125 的氨基酸序列为Thr Thr Pro Ala Gln Gly Asn Ser Met PhePro Ser Cys Cys Cys Thr Lys Pro Thr Asp Gly0本发明提供的携带有乙肝病毒S2[8]抗原表位的重组嵌合蛋白的氨基酸序列为 Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp Lys He ValGlu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu He Gln Gln Phe Asn Gln Met He IleThr Met Asn Gly Asn Glu Phe Gln Thr Gly Gly He Gly Asn Leu Pro Thr Arg Asn TrpSer Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val GluThr Ala Arg Asn Thr He Asp Tyr Phe Val Asp Phe Val Asp Asn Val Cys Met Asp GluMet Val Arg Glu Ser Gln Arg Asn Gly He Ala Pro Gln Ser Glu Ser Leu Arg Lys LeuSer Gly He Lys Phe Lys Arg He Asn Phe Asp Asn Ser Ser Glu Tyr He Glu Asn Trp Asn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro Asn He Phe ProTyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Ala His Glu Leu Met Gly Thr MetTrp Leu Asn Ala Gly Ser Glu He Gln Val Ala Gly Phe Asp Tyr Ser Asn He Gln GlnPhe Glu His He Val Gln Leu Arg Arg Val Leu Thr Thr Ala Thr He Thr Leu Leu ProAsp Ala Glu Arg Phe Ser Phe Pro Arg Val He Asn Ser Ala Asp Gly Thr Thr Trp TyrPhe Asn Pro Val He Leu Arg Pro Asn Asn Val Glu Val Glu Phe Leu Leu Asn Gly GlnHe He Asn Thr Tyr Gln Ala Pro Arg Phe His Gln Ala Leu Gln Asp Pro Arg Val ArgGly Leu Tyr Phe Pro Ala Gly Pro Arg Phe Gly Thr He Val Ala Arg Asn Phe Asp ThrHe Arg Leu Ser Phe Gln Leu Met Arg Pro Arg Thr Pro Ser Val Ala Ala Leu Glu HisHis Ala Thr Val Gly Leu Thr Leu Arg He Glu Ser Ala He Cys Glu Ser Val Leu AlaAsp Ala Ser Glu Thr Met Leu Ala Asn Val Thr Ser Val Arg Gln Glu Tyr Ala lie ProVal Gly Pro Val Phe Pro Pro Gly Met Asn Trp Thr Asp Leu lie Thr Asn Tyr Ser ProSer Arg Glu Asp Asn Leu Gln Arg Val Phe Thr Val Ala Ser lie Arg Ser Met Leu ValLys o 所述抗原表位S2 [8]的氨基酸序列为Pro Arg Phe His Gln Ala Leu Gln AspPro Arg Val Arg Gly Leu Tyr Phe Pro Ala Gly。本发明提供的携带有乙肝病毒Sl[93]抗原表位的重组嵌合蛋白的氨基酸序列为
Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp Lys He ValGlu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu He Gln Gln Phe Asn Gln Met He IleThr Met Asn Gly Asn Glu Phe Gln Thr Gly Gly He Gly Asn Leu Pro Thr Arg Asn TrpSer Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val GluThr Ala Arg Asn Thr He Asp Tyr Phe Val Asp Phe Val Asp Asn Val Cys Met Asp GluMet Val Arg Glu Ser Gln Arg Asn Gly He Ala Pro Gln Ser Glu Ser Leu Arg Lys LeuSer Gly He Lys Phe Lys Arg He Asn Phe Asp Asn Ser Ser Glu Tyr He Glu Asn TrpAsn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro Asn He Phe ProTyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Ala His Glu Leu Met Gly Thr MetTrp Leu Asn Ala Gly Ser Glu He Gln Val Ala Gly Phe Asp Tyr Ser Asn He Gln GlnPhe Glu His He Val Gln Leu Arg Arg Val Leu Thr Thr Ala Thr He Thr Leu Leu ProAsp Ala Glu Arg Phe Ser Phe Pro Arg Val He Asn Ser Ala Asp Gly Thr Thr Trp TyrPhe Asn Pro Val He Leu Arg Pro Asn Asn Val Glu Val Glu Phe Leu Leu Asn Gly GlnHe He Asn Thr Tyr Gln Ala Pro Arg Phe Gly Thr He Val Ala Arg Asn Phe Asp ThrHe Arg Leu Ser Phe Gln Leu Met Arg Pro Arg Pro Pro Pro Ala Ser Thr Asn Arg GlnSer Gly Arg Gln Pro Arg Thr Pro Ser Val Ala Ala Leu Glu His His Ala Thr Val GlyLeu Thr Leu Arg He Glu Ser Ala He Cys Glu Ser Val Leu Ala Asp Ala Ser Glu ThrMet Leu Ala Asn Val Thr Ser Val Arg Gln Glu Tyr Ala He Pro Val Gly Pro Val PhePro Pro Gly Met Asn Trp Thr Asp Leu He Thr Asn Tyr Ser Pro Ser Arg Glu Asp AsnLeu Gln Arg Val Phe Thr Val Ala Ser He Arg Ser Met Leu Val Lys0所述抗原表位SI [93]的氨基酸序列为Pro Pro Pro Ala Ser Thr Asn Arg GlnSer Gly Arg Gin。本发明提供的携带有乙肝病毒C117抗原表位的重组嵌合蛋白的氨基酸序列为 Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp Lys He Val
Glu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu He Gln Gln Phe Asn Gln Met He IleThr Met Asn Gly Asn Glu Phe Gln Thr Gly Gly He Gly Asn Leu Pro Thr Arg Asn TrpSer Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val GluThr Ala Arg Asn Thr He Asp Tyr Phe Val Asp Phe Val Asp Asn Val Cys Met Asp GluMet Val Arg Glu Ser Gln Arg Asn Gly He Ala Pro Gln Ser Glu Ser Leu Arg Lys LeuSer Gly He Lys Phe Lys Arg He Asn Phe Asp Asn Ser Ser Glu Tyr He Glu Asn TrpAsn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro Asn He Phe ProTyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Ala His Glu Leu Met Gly Thr MetTrp Leu Asn Ala Gly Ser Glu He Gln Val Ala Gly Phe Asp Tyr Ser Asn lie Gln GlnPhe Glu His He Val Gln Leu Arg Arg Val Leu Thr Thr Ala Thr lie Thr Leu Leu ProAsp Ala Glu Arg Phe Ser Phe Pro Arg Val lie Asn Ser Ala Asp Gly Thr Thr Trp TyrPhe Asn Pro Val He Leu Arg Pro Asn Asn Val Glu Val Glu Phe Leu Leu Asn Gly GlnHe He Asn Thr Tyr Gln Ala Pro Arg Phe Gly Thr lie Val Ala Arg Asn Phe Asp ThrHe Arg Leu Ser Phe Gln Leu Met Arg Pro Arg Thr Pro Ser Val Ala Ala Leu Glu TyrLeu Val Ser Phe Gly Val Trp He Arg Thr Pro Pro Ala Tyr Arg Pro Pro Asn Ala ProHe Leu Glu His His Ala Thr Val Gly Leu Thr Leu Arg lie Glu Ser Ala lie Cys GluSer Val Leu Ala Asp Ala Ser Glu Thr Met Leu Ala Asn Val Thr Ser Val Arg Gln GluTyr Ala He Pro Val Gly Pro Val Phe Pro Pro Gly Met Asn Trp Thr Asp Leu lie ThrAsn Tyr Ser Pro Ser Arg Glu Asp Asn Leu Gln Arg Val Phe Thr Val Ala Ser lie ArgSer Met Leu Val Lys0 所述抗原表位Cl17 的氨基酸序列为Tyr Leu Val Ser Phe Gly Val Trp He ArgThr Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro lie。本发明提供的同时携带乙肝病毒S82,C19,S125,S2[8],SI [93]和C117抗原表位的重组嵌合蛋白的氨基酸序列为
Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp Lys He ValGlu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu He Gln Gln Phe Asn Gln Met He IleThr Met Asn Gly Asn Glu Phe Gln Thr Gly Gly He Gly Asn Leu Pro Thr Arg Asn TrpSer Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val GluThr Ala Arg Asn Thr He Asp Tyr Phe Val Asp Phe Val Asp Asn Val Cys Met Asp GluMet Val Arg Glu Ser Gln Arg Asn Gly He Ala Pro Gln Ser Glu Ser Leu Arg Lys LeuSer Gly He Lys Phe Lys Arg He Asn Phe Asp Asn Ser Ser Glu Tyr He Glu Asn TrpAsn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro Asn He Phe ProTyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Ala His Glu Leu Phe Leu Phe IleLeu Leu Leu Cys Leu Glu Leu Met Gly Thr Met Trp Leu Asn Ala Gly Ser Glu He GlnVal Ala Gly Phe Asp Tyr Ser Asn Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val ArgAsp Ser Asn He Gln Gln Phe Glu His He Val Gln Leu Arg Arg Val Leu Thr Thr AlaThr He Thr Leu Leu Pro Asp Ala Glu Arg Phe Ser Phe Pro Arg Val He Asn Ser AlaAsp Gly Thr Thr Pro Ala Gln Gly Asn Ser Met Phe Pro Ser Cys Cys Cys Thr Lys ProThr Asp Gly Thr Thr Trp Tyr Phe Asn Pro Val He Leu Arg Pro Asn Asn Val Glu ValGlu Phe Leu Leu Asn Gly Gln Ile He Asn Thr Tyr Gln Ala Pro Arg Phe His Gln AlaLeu Gln Asp Pro Arg Val Arg Gly Leu Tyr Phe Pro Ala Gly Pro Arg Phe Gly Thr IleVal Ala Arg Asn Phe Asp Thr He Arg Leu Ser Phe Gln Leu Met Arg Pro Arg Pro ProPro Ala Ser Thr Asn Arg Gln Ser Gly Arg Gln Pro Arg Thr Pro Ser Val Ala Ala LeuGlu Tyr Leu Val Ser Phe Gly Val Trp He Arg Thr Pro Pro Ala Tyr Arg Pro Pro AsnAla Pro He Leu Glu His His Ala Thr Val Gly Leu Thr Leu Arg He Glu Ser Ala IleCys Glu Ser Val Leu Ala Asp Ala Ser Glu Thr Met Leu Ala Asn Val Thr Ser Val ArgGln Glu Tyr Ala He Pro Val Gly Pro Val Phe Pro Pro Gly Met Asn Trp Thr Asp LeuHe Thr Asn Tyr Ser Pro Ser Arg Glu Asp Asn Leu Gln Arg Val Phe Thr Val Ala Serlie Arg Ser Met Leu Val Lys0本发明提供的携 带有乙肝病毒S82抗原表位的重组嵌合蛋白,携带有乙肝病毒C19抗原表位的重组嵌合蛋白,携带有乙肝病毒S125抗原表位的重组嵌合蛋白,携带有乙肝病毒S2[8]抗原表位的重组嵌合蛋白,携带有乙肝病毒Sl[93]抗原表位的重组嵌合蛋白,携带有乙肝病毒C117抗原表位的重组嵌合蛋白均通过下列步骤制备
IA、根据抗原表位氨基酸序列,分别设计下列引物
S82F CTTCCTCTTCATCCTGCTGCTATGCCTGGAGCT
S82R CCAGGCATAGCAGCAGGATGAAGAGGAAGAGCT
C19F CGAATCATTTTTGCCTTCTGACTTCTTTCCTTCCGTCCGGGATTTC19R CGAAATCCCGGACGGAAGGAAAGAAGTCAGAAGGCAAAAATGATTS125F CACTCCTGCTCAAGGCAACTCTATGTTTCCCTCATGTTGCTGTACAAAACCTACGGATGGTACS125R CATCCGTAGGTTTTGTACAGCAACATGAGGGAAACATAGAGTTGCCTTGAGCAGGAGTGGTACS2[8] F CTAGGTTCCACCAAGCTCTGCAAGATCCCAGAGTCAGGGGCCTGTATTTTCCTGCTGGTCS2 [8] R CTAGGACCAGCAGGAAAATACAGGCCCCTGACTCTGGGATCTTGCAGAGCTTGGTGGAACSI[93]F GGCCTCCTCCTGCCTCCACCAATCGGCAGTCAGGAAGGCAGCCGC
SI[93] R GGCTGCCTTCCTGACTGCCGATTGGTGGAGGCAGGAGGAGGCCGC
C117F TCGAGTATTTGGTCTCTTTCGGAGTGTGGATTCGCACTCCACCAGCTTATAGACCACCAAATGCCCCTATCC
C117R TCGAGGATAGGGGCATTTGGTGGTCTATAAGCTGGTGGAGTGCGAATCCACACTCCGAAAGAGACCAAATAC ;
IB、将步骤IA的各个抗原表位的引物进行如下配对
将S抗原表位S82的两条人工合成的寡核苷酸即正链S82F和负链S82R配成引物对S82F/S82R ;
将C抗原表位C19,其氛基酸序列为Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser ValArg Asp的两条人工合成的寡核苷酸即正链(C19F)和负链(C19R)配成引物对C19F/C19R;
将S抗原表位S125的两条人工合成的寡核苷酸即正链S125F和负链S125R配成引物对 S125F/S125R ;
将PreS2抗原表位S2 [8]的两条人工合成的寡核苷酸即正链S2 [8] F和负链S2 [8] R配成引物对 S2[8]F/S2[8]R;
将PreSl抗原表位SI [93]的两条人工合成的寡核苷酸即正链SI [93]F和负链SI [93]R 配成引物对 SI [93JF/S1 [93] R ;
将C抗原表位Cl 17的两条人工合成的寡核苷酸即正链C117F和负链C117R配成引物对 C117F/C117R。1C、将步骤IB的各引物对分别在下列条件下进行退火,退火混合液中分别含有2μ I的正向引物,2 μ I的反向引物,以及7μ I的PCR缓冲液和59 μ I的水;将退火混合液在65°C水浴反应5分钟后,放入37°C水浴反应45分钟,反应体系中加入400 μ I的TE,并与等体积异丙醇充分混勻,室温放置10分钟后,4°C, 15,OOOrpm离心15min,沉淀用质量浓度为75%的乙醇漂洗,干燥后,用 ομ I的TE溶解;分别得到在5’端和3’端分别带Sac I位点,或者BspT104 I位点,或者Kpn I位点,或者Bln I位点,或者Sac II位点,或者XhoI位点的下列六作互补双链S82互补双链;C19互补双链;S125互补双链;S2[8]互补双链;SI [93]互补双链;C117互补双链;
1D、将携带有 Sac HliUBspTKM I 位点、Kpn I (ggtacc)位点、Sac II (ccgcgg)位点、Sac II (CCRCRR)位点及Xho I (ctcRaR)位点的重组轮状病毒VP6载体蛋白编码基因的质粒PETP6F,在下列条件下分别用Sac I,BspT104 I, Kpn I, Bln I, Sac II7Xho I酶切酶切混合液分别含3μ I的Sac I,BspT104 I,Kpn I,Bln I,Sac II或Xho I内切酶(15U),以及10 μ I的pETP6F DNA, 7 μ I的IOX缓冲液,50 μ I的水;将酶切混合液放于37°C水浴反应3小时,得下列六个酶切质粒片段Sac I酶切质粒片段;BspT104 I酶切质粒片段;Kpn I酶切质粒片段;Β1η I酶切质粒片段;Sac II酶切质粒片段;Xho I酶切质粒片段;用I. 5%的琼脂糖凝胶电泳分离和纯化所得六个带有不同切口的酶切质粒片段;
IE、将步骤ID所得六个酶切质粒片段分别与步骤IC所得六个互补双链配对如下
Sac I酶切质粒片段/S82互补双链;
BspT104 I酶切质粒片段/C19互补双链;
Kpn I酶切质粒片段/S125互补双链;
Bln I酶切质粒片段/S2[8]互补双链;
Sac II酶切质粒片段/SI [93]互补双链;
Xho I酶切质粒片段/Cl 17互补双链;
将上述配对的各片段分别与T4 DNA连接酶及缓冲液混合后,在18°C连接反应6h,分别得到下列六个重组质粒
在Sac I位点携带有S82抗原表位基因的重组质粒pETP6F/S82 ;
在BspT104 I位点携带有C19抗原表位基因的重组质粒pETP6F/C19 ;
在Kpn I位点携带有S125抗原表位基因的重组质粒pETP6F/S125 ;
在Bln I位点携带有S2[8]抗原表位基因的重组质粒pETP6F/S2[8];
在Sac II位点携带有SI [93]抗原表位基因的重组质粒pETP6F/Sl [93];
在Xho I位点携带有Cl 17抗原表位基因的重组质粒pETP6F/C117 ;
按常规分别将所得重组质粒经菌体转化扩增后,进行酶切鉴定和核苷酸序列测定;
IF、将步骤IE 得到的六个重组质粒,即 pETP6F/S82,pETP6F/C19, pETP6F236K/S125,pETP6F268B/S2[8], pETP6F290S/Sl [93],pETP6F298X/C117 在下列条件下分别转化 BL21(DE3)感受态细胞10 μ I的重组质粒与100 μ I BL21 (DE3)感受态细胞混匀,冰上放置30分钟,42°C放置70秒钟,加入500 μ I LB培养液后,在37°C培养30分钟,培养板涂含200 μ g/ml氨苄青霉素的I. 5%琼脂培养板,培养板于37°C培养14个小时,挑取单个菌落放入含200 μ g/ml氨苄青霉素的LB培养液中培养和表达,得到携带有不同抗原表位的下列六个重组蛋白
(1)携带乙肝病毒S82抗原表位的重组蛋白rVP6F/S82;
(2)携带乙肝病毒C19抗原表位的重组蛋白rVP6F/C19;
(3)携带乙肝病毒S125抗原表位的重组蛋白rVP6F/S125;
(4)携带乙肝病毒S2[8]抗原表位的重组蛋白rVP6F/S2[8];(5)携带乙肝病毒SI[93]抗原表位的重组蛋白rVP6F/Sl[93];
(6)携带乙肝病毒C117抗原表位的重组蛋白rVP6F/C117。本发明提供的同时携带乙肝病毒S82,C19,S125,S2[8],S1[93]和C117抗原表位的重组蛋白通过下列步骤制备
2A、同上述IA ;
2B、同上述IB ;
2C、同上述IC ;
2D、同上述ID ;
2E、同上述IE ;
2F、将步骤2E所得重组质粒pETP6F/S82用Bspt 104 I酶切,并与步骤2C所得C19互补双链连接,得到在Sac I和BspT104 I位点携带有S82和C19抗原表位基因的重组质粒PETP6F/S82/C19 ;
2G、将步骤2E所得重组质粒pETP6F/S82/C19用Kpn I酶切,并与步骤2C所得S125互补双链连接,得到在Sac I, BspT104 I和Kpn I位点携带有S82, C19和S125抗原表位基因的重组质粒 PETP6F/S82/C19/S125 ;
2H、将步骤2E所得重组质粒pETP6F/S82/C19/S125用Bln I酶切,并与步骤2C所得S2[8]互补双链连接,得到在Sac I,BspT104 I, Kpn I和Bln I位点携带有S82,C19,S125和S2[8]抗原表位基因的重组质粒pETP6F/S82/C19/S125/S2[8];
21、将步骤2E所得重组质粒pETP6F/S82/C19/S125/S2[8]用Sac II酶切,并与步骤2C所得SI [93]互补双链连接,得到在Sac I, BspT104 I,Kpn I,Bln I和Sac II位点携带有 S82,C19,S125,S2[8]和 SI [93]抗原表位基因的重组质粒pETP6F/S82/C19/S125/S2[8]/S1[93];
2J、将步骤2E所得重组质粒pETP6F/S82/C19/S125/S2[8]/Sl[93]用Xho I酶切,并与步骤2C所得C117互补双链连接,得到在Sac I, BspT104 I,Kpn I,Bln I, Sac II和Xho I位点携带有对应的S82,C19,S125,S2 [8],SI [93]和Cl 17抗原表位基因的重组质粒pETP6F/VP⑥H ;按常规将所得重组质粒经菌体转化扩增后,进行酶切鉴定和核苷酸序列测定;
2K、将步骤2J得到的重组质粒pETP6F/VP⑥H在下列条件下转化BL21(DE3)感受态细胞10 μ I的步骤2J所得重组质粒与100 μ I BL21 (DE3)感受态细胞混匀,冰上放置30分钟,42 V放置70秒钟,加入500 μ I LB培养液后,在37°C培养30分钟。培养物涂含200 μ g/ml氨苄青霉素的I. 5%琼脂培养板;培养板放37°C培养箱中培养14个小时,挑取单个菌落放入含200 μ g/ml氨苄青霉素的LB培养液中培养和表达,得携带乙肝病毒S82,C19,S125,S2[8],S1[93]和Cl 17抗原表位的重组蛋白rVP⑥H。所述步骤ID或2D的携带有Sac I位点、BspT104 I位点、Kpn I位点、Bln I位点、Sac II位点及Xho I位点的重组轮状病毒VP6载体蛋白编码基因的质粒pETP6F通过下列步骤构建
I)人工设计下列引物对
P174F CATGAGCTCATGGGTACAATGTGG ;
P174R CATGAGCTCATGCGCAGGTTGTGA ;
P197F GATTATTCGAACATACAGCAATTTGAGCAT ;P197R TATGTTCGAATAATCAAATCCAGCAAC ;
P244F GATGGTACCACATGGTATTTTAATCCA ;
P244R ;TGTGGTACCATCAGCTGAATTAATTAC ;
P275F GCACCTAGGTTTGGTACAATTGTA ;
P275R AAACCTAGGTGCCTGATAAGTATTTAT ;
P298F AGACCGCGGACCCCATCAGTCGCA ;
P298R GGTCCGCGGTCTCATCAATTGAAATGA ; P308F GCACTCGAGCATCATGCTACTGTA ;
P308R ATGCTCGAGTGCTGCGACTGATGG ;
以及下列引物
PETL5 ATCATATGGAGGTTCTGTACTC ;
PVP6-3 TAGGATCCTTATCATTTAACAAGCATGCTTCTAAT ;
2)以轮状病毒TB-Chen株VP6蛋白编码基因为模板,以下列为引物对,进行PCR扩增 PETL5/P174R 和 P174F/PVP6-3 ;
PETL5/P197R 和 P197F/PVP6-3 ;
PETL5/P244R 和 P244F/PVP6-3 ;
PETL5/P275R 和 P275F/PVP6-3 ;
PETL5/P298R 和 P298F/PVP6-3 ;
PETL5/P308R 和 P308F/PVP6-3 ;
具体是
在PCR反应体系为PCR反应混合液体积为100 μ I,包含30ng模板DNA,I X IO5 pmol的dNTPs, IOX PCR缓冲液 10μ 1,5U Taq DNA聚合酶,60pmol 的引物对PETL5/P174R和P174F/PVP6-3,其余用水补足;PCR反应条件为94°C预变性3 min,94°C变性40s,56°C复性30s,72°C延伸反应lmin,共40个循环,最后72°C延伸10 min ;得到带有NdeI和Sac I位点序列的PCR扩增片段6174F和带有Sac I和BamH I位点序列的PCR扩增片段6174R ;用I. 5%的琼脂糖凝胶电泳分离和纯化该扩增片段;将PCR扩增片段6174F和6174R分别用Nde I/Sac I 和 Sac I/BamH I 双酶切,即
A、6174F酶切片段制备酶切反应体系为3μI的6174F片段,3 μ I的Nde I (15U),3μ I的Sac I (15U),8y I的IOX缓冲液,63 μ I的水;将酶切混合液分别于37°C水浴反应3小时后,得酶切片段,用I. 5%的琼脂糖凝胶电泳分离和纯化该酶切片段;
B、除使用SacI/BamH I双酶切外,6174R酶切片段制备与6174F酶切片段相同;
C、酶切片段的连接将6174F和6174R酶切片段与T4DNA连接酶及缓冲液混合后,在18°C连接反应6h,得到携带有Sac I位点(gagctc)的VP6编码基因
3)运用步骤2)的PCR扩增、酶切和连接,使用对应的PETL5/P197R和P197F/PVP6-3引物对及内切酶Nde I/BspT104 I和BspT104 I/BamH I,在步骤2)获得的携带有Sac I位点的VP6编码基因上插入BspT104 I (ttcgaa)位点,得到携带有Sac I位点和BspT104 I位点的VP6编码基因;
4 )用与步骤2 )相同的PCR扩增、酶切和连接,使用对应的PETL5/P244R和P244F/PVP6-3引物对及内切酶Nde I/Kpn I和Kpn I/BamH I,在步骤3)所得携带有Sac I位点和BspT104 I位点的VP6编码基因上插入Kpn I (RRtacc)位点,得到携带有Sac I位点、BspT104 I位点及Kpn I (ggtacc)位点的VP6编码某因
5)用与步骤2)相同的PCR扩增、酶切和连接,使用对应的PETL5/P275R和P275F/PVP6-3引物对及内切酶Nde I/Bln I和Bin I/BamH I,在步骤4)所得携带有Sac I位点、BspT104 I位点及Kpn I (ggtacc)位点的VP6编码基因上插入Bln I (cctagg)位点,得至Ij携带有 Sac I 位点、BspT104 I 位点、Kpn I (ggtacc)位点及 Bln I (cctagg)位点的 VP6编码基因;
6)用与步骤2)相同的PCR扩增、酶切和连接,使用对应的PETL5/P298R和P298F/PVP6-3引物对及内切酶Nde I/Sac II和Sac I I/BamH I,在步骤5)所得携带有Sac I位点、BspT104 I位点、Kpn I (ggtacc)位点及Bln I (cctagg)位点的VP6编码基因上插入Sac II (ccgcgg)位点,得到携带有 Sac I 位点、BspT104 I 位点、Kpn I (ggtacc)位点、SacII (ccgcgg)位点及Sac II (ccgcgg)位点的VP6编码基因;
7)、用与步骤2)相同的PCR扩增、酶切和连接,使用对应的PETL5/P308R和P308F/PVP6-3引物对及内切酶Nde I/Xho I和Xho I/BamH I,在步骤6)所得携带有Sac I位点、BspT104 I 位点、Kpn I (ggtacc)位点、Bln I (ccgcgg)位点及 Sac II (ccgcgg)位点的VP6编码基因上插入Xho I (ctcgag)位点,得到携带有Sac I位点、BspT104 I位点、KpnI (ggtacc)位点、Bln I (ccgcgg)位点、Sac II (ccgcgg)位点及 Xho I (ctcgag)位点的VP6载体蛋白编码基因,该VP6F载体蛋白编码基因由1146个核苷酸组成,前端为编码蛋氨酸(M)的起始秘密子ATG,末端由2个终止密码子(TGA TAA)组成,其核苷酸序列为
Iatggatgttt tgtattcatt atcaaaaact cttaaggatg ctagagacaa 51 aattgtcgaa ggcactttat actctaatgt tagtgatcta attcaacaat 101 ttaatcaaat gataattact atgaatggaa atgaatttca aactggagga 151 attggtaatc taccaaccag aaattggagt tttgattttg gtttacttgg 201 aactacgctt ttgaatttag atgccaatta tgttgaaact gcgcgtaaca 251 caattgatta ttttgttgat tttgtagata acgtatgtat ggatgagatg 301 gttagagaat cacaaagaaa cggaattgca ccgcagtcag aatcacttag 351 aaaactatca gggattaagt ttaaaagaat aaattttgac aattcgtcgg 401 aatacataga aaactggaac ttgcaaaata gaagacaaag aactggtttt 451 acatttcata aaccaaacat ctttccatat tcagcttcat ttacgttaaa 501 tagatcacaa cctgcgcatg_agctcatggg tacaatgtgg ttgaatgcag 551 gttcagagat tcaagttgct ggatttgatt attcRaacat acagcaattt 601 gagcatatag ttcagctccg tagggtgtta acgacggcta caataactct 651 tttaccagat gctgaaaggt ttagtttccc tagagtaatt aattcagctg 701 atRRtaccac atggtatttt aatccagtaa tacttagacc gaataatgtc 751 gaagtagaat ttctattgaa tggacagata ataaatactt atcaggcacc 801 taggtttggt acaattgtag ctagaaattt tgatactatt agattatcat 851 ttcaattgat gagaccgcgg accccatcag tcRcaRcact CRaRcatcat 901 gctactgtag gactaacatt acgcattgaa tctgcaattt gtgagtcagt 951 gcttgctgat gctagtgaaa caatgttagc taatgtaaca tctgttagac1001 aagaatatgc aataccagtt gggccagttt ttccaccagg tatgaattgg1051 actgatttga ttactaacta ctcaccatct agagaggata atttacaacg1101 tgtgtttaca gtagcttcca ttagaagcat gcttgttaaa tgataa
8)、将步骤7)得到的VP6载体蛋白编码基因用常规的基因克隆和重组技术,连接到ρΕΤ表达质粒DNA的Nde I/BamH I位点,得到携带VP6F载体蛋白编码基因的重组质粒pET6F。
所述步骤2 )的轮状病毒TB-Chen株为公知的病毒株。本发明具有下列优点和效果采用上述方案获得的各个携带乙肝病毒不同抗原表位的重组蛋白,经免疫学Western B lot检测,结果表明,所述各个重组蛋白不仅具有VP6F蛋白的抗原反应性与免疫原性,还具有HBV抗原表位的抗原反应性和免疫原性,且不具有传染性,没有毒力返祖和肠套叠等副作用,对开发新一代RV/HBV重组嵌合疫苗及试剂具有重要价值。

通过下列步骤构建携带有Sac I位点、BspT104 I位点、Kpn I位点、Bln I位点、SacII位点及Xho I位点的重组轮状病毒VP6载体蛋白编码基因的质粒PETP6F 1)人工设计下列引物对
P174F CATGAGCTCATGGGTACAATGTGG ;
P174R CATGAGCTCATGCGCAGGTTGTGA ;
P197F GATTATTCGAACATACAGCAATTTGAGCAT ;
P197R TATGTTCGAATAATCAAATCCAGCAAC ;
P244F GATGGTACCACATGGTATTTTAATCCA ;
P244R ; TGTGGTACCATCAGCTGAATTAATTAC ;
P275F GCACCTAGGTTTGGTACAATTGTA ;
P275R AAACCTAGGTGCCTGATAAGTATTTAT ;
P298F AGACCGCGGACCCCATCAGTCGCA ;
P298R GGTCCGCGGTCTCATCAATTGAAATGA ;
P308F GCACTCGAGCATCATGCTACTGTA ;
P308R ATGCTCGAGTGCTGCGACTGATGG ;
以及下列引物
PETL5 ATCATATGGAGGTTCTGTACTC ;
PVP6-3 TAGGATCCTTATCATTTAACAAGCATGCTTCTAAT ;
2)以公知的轮状病毒TB-Chen株VP6蛋白编码基因为模板,以下列为引物对,进行PCR扩增PETL5/P174R 和 P174F/PVP6-3 ;
PETL5/P197R 和 P197F/PVP6-3 ;
PETL5/P244R 和 P244F/PVP6-3 ;
PETL5/P275R 和 P275F/PVP6-3 ;
PETL5/P298R 和 P298F/PVP6-3 ;PETL5/P308R 和 P308F/PVP6-3 ;
具体是
在PCR反应体系为PCR反应混合液体积为100 μ I,包含30ng模板DNA,I X IO5 pmol的dNTPs, IOX PCR缓冲液 10μ 1,5U Taq DNA聚合酶,60pmol 的引物对PETL5/P174R和P174F/PVP6-3,其余用水补足;PCR反应条件为94°C预变性3 min,94°C变性40s,56°C复性30s,72°C延伸反应lmin,共40个循环,最后72°C延伸10 min ;得到带有NdeI和Sac I位点序列的PCR扩增片段6174F和带有Sac I和BamH I位点序列的PCR扩增片段6174R ;用I. 5%的琼脂糖凝胶电泳分离和纯化该扩增片段;将PCR扩增片段6174F和6174R分别用Nde I/Sac I 和 Sac I/BamH I 双酶切,即
A、6174F酶切片段制备酶切反应体系为3μI的6174F片段,3 μ I的Nde I (15U),3μ I的Sac I (15U),8y I的IOX缓冲液,63 μ I的水;将酶切混合液分别于37°C水浴反 应3小时后,得酶切片段,用I. 5%的琼脂糖凝胶电泳分离和纯化该酶切片段;
B、除使用SacI/BamH I双酶切外,6174R酶切片段制备与6174F酶切片段相同;
C、酶切片段的连接将6174F和6174R酶切片段与T4DNA连接酶及缓冲液混合后,在18°C连接反应6h,得到携带有Sac I位点(gagctc)的VP6编码基因
3)运用步骤2)的PCR扩增、酶切和连接,使用对应的PETL5/P197R和P197F/PVP6-3引物对及内切酶Nde I/BspT104 I和BspT104 I/BamH I,在步骤2)获得的携带有Sac I位点的VP6编码基因上插入BspT104 I (ttcgaa)位点,得到携带有Sac I位点和BspT104 I位点的VP6编码基因;
4 )用与步骤2 )相同的PCR扩增、酶切和连接,使用对应的PETL5/P244R和P244F/PVP6-3引物对及内切酶Nde I/Kpn I和Kpn I/BamH I,在步骤3)所得携带有Sac I位点和BspT104 I位点的VP6编码基因上插入Kpn I (ggtacc)位点,得到携带有Sac I位点、BspT104 I位点及Kpn I (ggtacc)位点的VP6编码基因;
5)用与步骤2)相同的PCR扩增、酶切和连接,使用对应的PETL5/P275R和P275F/PVP6-3引物对及内切酶Nde I/Bln I和Bin I/BamH I,在步骤4)所得携带有Sac I位点、BspT104 I位点及Kpn I (ggtacc)位点的VP6编码基因上插入Bln I (cctagg)位点,得到携带有 Sac I 位点、BspT104 I 位点、Kpn I (ggtacc)位点及 Bln I (cctagg)位点的 VP6编码基因;
6 )用与步骤2 )相同的PCR扩增、酶切和连接,使用对应的PETL5/P298R和P298F/PVP6-3引物对及内切酶Nde I/Sac II和Sac I I/BamH I,在步骤5)所得携带有Sac I位点、BspT104 I位点、Kpn I (ggtacc)位点及Bln I (cctagg)位点的VP6编码基因上插入Sac II (ccgcgg)位点,得到携带有 Sac I 位点、BspT104 I 位点、Kpn I (ggtacc)位点、Sac
II(ccgcgg)位点及Sac II (ccgcgg)位点的VP6编码基因;
7)、用与步骤2)相同的PCR扩增、酶切和连接,使用对应的PETL5/P308R和P308F/PVP6-3引物对及内切酶Nde I/Xho I和Xho I/BamH I,在步骤6)所得携带有Sac I位点、BspT104 I 位点、Kpn I (ggtacc)位点、Bln I (ccgcgg)位点及 Sac II (ccgcgg)位点的VP6编码基因上插入Xho I (ctcgag)位点,得到携带有Sac I位点、BspT104 I位点、Kpn
I(ggtacc)位点、Bln I (ccgcgg)位点、Sac II (ccgcgg)位点及 Xho I (ctcgag)位点的VP6载体蛋白编码基因,该VP6F载体蛋白编码基因由1146个核苷酸组成,前端为编码蛋氨酸(M)的起始秘密子ATG,末端由2个终止密码子(TGA TAA)组成,其核苷酸序列为
I atggatgttt tgtattcatt atcaaaaact cttaaggatg ctagagacaa51 aattgtcgaa ggcactttat actctaatgt tagtgatcta attcaacaat101 ttaatcaaat gataattact atgaatggaa atgaatttca aactggagga151 attggtaatc taccaaccag aaattggagt tttgattttg gtttacttgg201 aactacgctt ttgaatttag atgccaatta tgttgaaact gcgcgtaaca251 caattgatta ttttgttgat tttgtagata acgtatgtat ggatgagatg301 gttagagaat cacaaagaaa cggaattgca ccgcagtcag aatcacttag351 aaaactatca gggattaagt ttaaaagaat aaattttgac aattcgtcgg401 aatacataga aaactggaac ttgcaaaata gaagacaaag aactggtttt451 acatttcata aaccaaacat ctttccatat tcagcttcat ttacgttaaa501 tagatcacaa cctgcgcatg_agctcatggg tacaatgtgg ttgaatgcag551 gttcagagat tcaagttgct ggatttgatt attcgaacat acagcaattt 601 gagcatatag ttcagctccg tagggtgtta acgacggcta caataactct651 tttaccagat gctgaaaggt ttagtttccc tagagtaatt aattcagctg701 atggtaccac atggtatttt aatccagtaa tacttagacc gaataatgtc751 gaagtagaat ttctattgaa tggacagata ataaatactt atcaggcacc801 taggtttggt acaattgtag ctagaaattt tgatactatt agattatcat851 ttcaattgat gagaccgcgg accccatcag tcgcagcact cgagcatcat901 gctactgtag gactaacatt acgcattgaa tctgcaattt gtgagtcagt951 gcttgctgat gctagtgaaa caatgttagc taatgtaaca tctgttagac
1001 aagaatatgc aataccagtt gggccagttt ttccaccagg tatgaattgg
1051 actgatttga ttactaacta ctcaccatct agagaggata atttacaacg
1101 tgtgtttaca gtagcttcca ttagaagcat gcttgttaaa tgataa
8)、将步骤7)得到的VP6载体蛋白编码基因用常规的基因克隆和重组技术,连接到ρΕΤ表达质粒DNA的Nde I/BamH I位点,得到携带VP6F载体蛋白编码基因的重组质粒pET6F。实施例2
本发明提供的携带有乙肝病毒S82抗原表位的重组嵌合蛋白通过下列步骤制备 A、根据抗原表位氨基酸序列,分别设计下列引物
S82F CTTCCTCTTCATCCTGCTGCTATGCCTGGAGCT
S82R CCAGGCATAGCAGCAGGATGAAGAGGAAGAGCT
B、将步骤A的引物进行如下配对将S抗原表位S82的两条人工合成的寡核苷酸即正链S82F和负链S82R配成引物对S82F/S82R ;C、将步骤B的引物对在下列条件下进行退火,退火混合液中分别含有2μI的正向引物,2 μ I的反向引物,以及7 μ I的PCR缓冲液和59 μ I的水;将退火混合液在65°C水浴反应5分钟后,放入37°C水浴反应45分钟,反应体系中加入400 μ I的TE,并与等体积异丙醇充分混匀,室温放置10分钟后,4°C,15,OOOrpm离心15min,沉淀用质量浓度为75%的乙醇漂洗,干燥后,用IOyl的TE溶解;得到在5’端和3’端分别带Sac I位点的互补双链S82互补双链;
D、将携带有SacI位点的重组轮状病毒VP6载体蛋白编码基因的质粒pETP6F,在下列条件下用Sac I酶切酶切混合液含3 μ I的Sac I内切酶(15U),以及10 μ I的pETP6FDNA, 7 μ I的10 X缓冲液,50 μ I的水;将酶切混合液放于37°C水浴反应3小时,得Sac I酶切质粒片段;用I. 5%的琼脂糖凝胶电泳分离和纯化所得酶切质粒片段;
E、将步骤D所得酶切质粒片段与步骤C所得互补双链配对如下 Sac I酶切质粒片段/S82互补双链; 将上述配对的片段与T4 DNA连接酶及缓冲液混合后,在18°C连接反应6h,得到在SacI位点携带有S82抗原表位基因的重组质粒pETP6F/S82 ;按常规分别将所得重组质粒经菌体转化扩增后,进行酶切鉴定和核苷酸序列测定;
F、将步骤E得到的重组质粒,即PETP6F/S82,在下列条件下分别转化BL21(DE3)感受态细胞10μ I的重组质粒与100 μ I BL21 (DE3)感受态细胞混匀,冰上放置30分钟,42°C放置70秒钟,加入500 μ I LB培养液后,在37°C培养30分钟,培养板涂含200 μ g/ml氨苄青霉素的I. 5%琼脂培养板,培养板于37°C培养14个小时,挑取单个菌落放入含200 μ g/ml氨苄青霉素的LB培养液中培养和表达,得到携带乙肝病毒S82抗原表位的重组蛋白rVP6/S82。实施例3
A、引物设计为
C19F CGAATCATTTTTGCCTTCTGACTTCTTTCCTTCCGTCCGGGATTTC19R CGAAATCCCGGACGGAAGGAAAGAAGTCAGAAGGCAAAAATGATT
B、引物配对为
将C抗原表位C19,其氛基酸序列为Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser ValArg Asp的两条人工合成的寡核苷酸即正链(C19F)和负链(C19R)配成引物对C19F/C19R ;
C、同实施例2 D、将携带有BspT104I位点的重组轮状病毒VP6载体蛋白编码基因的质粒pETP6F,在与实施例2步骤D相同条件下用BspT104 I酶切,得酶切质粒片段BspT104 I酶切质粒片段;
E、将步骤D所得酶切质粒片段与步骤C所得互补双链配对如下
BspT104 I酶切质粒片段/C19互补双链;
将上述配对的片段与T4 DNA连接酶及缓冲液混合后,在18°C连接反应6h,得到在BspT104 I位点携带有C19抗原表位基因的重组质粒pETP6F/C19 ;
F、将步骤E得到的重组质粒pETP6F/C19在与实施例2步骤F相同的条件下转化BL21(DE3)感受态细胞,得到携带乙肝病毒C19抗原表位的重组蛋白rVP6F/C19。实施例4 除引物为
S125F CACTCCTGCTCAAGGCAACTCTATGTTTCCCTCATGTTGCTGTACAAAACCTACGGATGGTACS125R CATCCGTAGGTTTTGTACAGCAACATGAGGGAAACATAGAGTTGCCTTGAGCAGGAGTGGTAC酶切时将携带有Kpn I (ggtacc)位点的重组轮状病毒VP6载体蛋白编码基因的质粒PETP6F,用Kpn I酶切外,其余均同实施例2,得到携带乙肝病毒S125抗原表位的重组蛋白rVP6F/S1250实施例5
除引物为
S2[8]F CTAGGTTCCACCAAGCTCTGCAAGATCCCAGAGTCAGGGGCCTGTATTTTCCTGCTGGTC
S2[8] R CTAGGACCAGCAGGAAAATACAGGCCCCTGACTCTGGGATCTTGCAGAGCTTGGTGGAAC酶切时将将携带有Bin I (ccgcgg)位点的重组轮状病毒VP6载体蛋白编码基因的质粒pETP6F,用Bln I酶切外,其余均同实施例2,得到携带乙肝病毒S2[8]抗原表位的重组蛋白 rVP6F/S2[8]。实施例6 除引物为
SI[93]F GGCCTCCTCCTGCCTCCACCAATCGGCAGTCAGGAAGGCAGCCGCSI[93] R GGCTGCCTTCCTGACTGCCGATTGGTGGAGGCAGGAGGAGGCCGC酶切时将将携带有Sac II (ccgcgg)位点的重组轮状病毒VP6载体蛋白编码基因的质粒PETP6F,用Sac II酶切外,其余均同实施例2,得到携带乙肝病毒SI [93]抗原表位的重组蛋白 rVP6F/Sl[93]。实施例7 除引物为
C117F TCGAGTATTTGGTCTCTTTCGGAGTGTGGATTCGCACTCCACCAGCTTATAGACCACCAAATGCCCCTATCC
C117R TCGAGGATAGGGGCATTTGGTGGTCTATAAGCTGGTGGAGTGCGAATCCACACTCCGAAAGAGACCAAATAC ;
酶切时将将携带有Xho I (ctcgag)位点的重组轮状病毒VP6载体蛋白编码基因的质粒PETP6F,用Xho I酶切外,其余均同实施例2,得到携带乙肝病毒C117抗原表位的重组蛋白 rVP6F/C1170实施例8
本发明提供的同时携带乙肝病毒S82,C19,S125,S2[8],S1[93]和C117抗原表位的重组蛋白通过下列步骤制备A、同实施例2步骤A;
B、同实施例2步骤B;
C、同实施例2步骤C;
D、同实施例2步骤D;
E、同实施例2步骤E;
F、将步骤E所得重组质粒pETP6F/S82用BspT104I酶切,并与步骤C所得C19互补双链连接,得到在Sac I和BspT104 I位点携带有S82和C19抗原表位基因的重组质粒pETP6F/S82/C19 ;
G、将步骤E所得重组质粒pETP6F/S82/C19用KpnI酶切,并与步骤C所得S125互补双链连接,得到在Sac I,BspT104 I和Kpn I位点携带有S82,C19和S125抗原表位基因的重组质粒 PETP6F/S82/C19/S125 ;
H、将步骤E所得重组质粒pETP6F/S82/C19/S125用BlnI酶切,并与步骤C所得S2 [8]互补双链连接,得到在Sac I,BspT104 I, Kpn I和Bin I位点携带有S82,C19,S125和S2[8]抗原表位基因的重组质粒pETP6F/S82/C19/S125/S2[8];
I、将步骤E所得重组质粒pETP6F/S82/C19/S125/S2[8]用Sac II酶切,并与步骤C所得Sl[93]互补双链连接,得到在Sac I,BspT104 I,Kpn I,Bln I和Sac II位点携带有S82,C19,S125,S2[8]和 SI [93]抗原表位基因的重组质粒pETP6F/S82/C19/S125/S2 [8] /SI[93];
J、将步骤E所得重组质粒pETP6F/S82/C19/S125/S2[8]/Sl[93]用Xho I酶切,并与步骤C所得Cl 17互补双链连接,得到在Sac I,BspT104 I,Kpn I,Bln I, Sac II和Xho I位点携带有对应的S82,C19,S125,S2[8],SI [93]和C117抗原表位基因的重组质粒pETP6F/VP⑥H ;按常规将所得重组质粒经菌体转化扩增后,进行酶切鉴定和核苷酸序列测定;
K、将步骤J得到的重组质粒pETP6F/VP⑥H在下列条件下转化BL21 (DE3)感受态细胞10 μ I重组质粒与100 μ I BL21 (DE3)感受态细胞混匀,并上放置30分钟,转42°C放置70秒钟,加入500 μ I LB培养液后,在37°C培养30分钟。培养物涂含200 μ g/ml氨苄青霉素的I. 5%琼脂培养板;培养板放37°C培养箱中培养14个小时,挑取单个菌落放入含200 μ g/ml氨苄青霉素的LB培养液中培养和表达,得同时携带乙肝病毒S82,C19,S125,S2[8],S1[93]和Cl 17抗原表位的重组蛋白rVP6F⑥H。本发明所得各个携带乙型肝炎病毒不同抗原表位的重组嵌合蛋白,经下列免疫学Western Blot 检测
1)将携带有乙肝病毒S82抗原表位的重组嵌合蛋白rVP6/S82,携带有乙肝病毒C19抗原表位的重组嵌合蛋白rVP6F/C19,携带有乙肝病毒S125抗原表位的重组嵌合蛋白rVP6F/S125,携带有乙肝病毒S2[8]抗原表位的重组嵌合蛋白rVP6F/S2[8],携带有乙肝病毒SI [93]抗原表位的重组嵌合蛋白rVP6F/Sl[93],携带有乙肝病毒C117抗原表位的重组嵌合蛋白rVP6F/C117,和同时携带乙肝病毒S82, C19, S125,S2[8],S1[93]和C117抗原表位的重组蛋白rVP6F⑥H,以及用作对照的重组轮状病毒NSP2蛋白,和用作对照的牛血清白蛋白,各取2μ g分别溶于20μ I水,分别加入5μ I 5Χ变性缓冲液,混匀后,在100°C变性5min ;
2)将上述I)的变性蛋白样品分别用10%聚丙烯酰胺凝胶电泳(10%SDS-PAGE)分离,并在电压15V、电流50mA的条件下电泳转印25 min,转移到PVDF膜上;将膜置于含5%脱脂奶粉的PBS/T液中于4° C封闭过夜;
3)用PBS/T洗膜5次,分别加入抗轮状病毒全病毒豚鼠血清抗体(5%脱脂奶粉1:400稀释),抗重组轮状病毒VP6蛋白豚鼠血清抗体(1%脱脂奶粉1:400稀释),抗重组轮状病毒NSP2蛋白豚鼠血清抗体(1%脱脂奶粉1:400稀释),HBsAb阳性的乙型肝炎患者的血清抗体(1%脱脂奶粉1:200稀释),HBcAb阳性的乙型肝炎患者的血清抗体(1%脱脂奶粉1:200稀释),于37°C孵育I. 5 h ;用PBS/T液洗膜5次,每次5 min ;
4)加入HRP标记的羊抗豚鼠IgG(1:2,000如上稀释)/ HRP标记的兔抗人IgG (1:800如上稀释),37°C孵育I h,用PBS/T漂洗5次,DAB显色;显色后,蒸馏水漂洗膜,终止显色,观察并分析结果如下 将携带有乙肝病毒S82抗原表位的重组嵌合蛋白rVP6/S82,携带有乙肝病毒C19抗原表位的重组嵌合蛋白rVP6F/C19,携带有乙肝病毒S125抗原表位的重组嵌合蛋白rVP6F/S125,携带有乙肝病毒S2[8]抗原表位的重组嵌合蛋白rVP6F/S2[8],携带有乙肝病毒SI [93]抗原表位的重组嵌合蛋白rVP6F/Sl[93],携带有乙肝病毒C117抗原表位的重组嵌合蛋白rVP6F/Cl 17,均能与抗轮状病毒全病毒抗体发生特异性免疫反应,能与抗轮状病毒VP6蛋白抗体发生特异性免疫反应,不能与抗重组轮状病毒NSP2蛋白豚鼠血清抗体发生特异性免疫反应。
将携带有乙肝病毒S82抗原表位的重组嵌合蛋白rVP6/S82,携带有乙肝病毒S125抗原表位的重组嵌合蛋白rVP6F/S125,携带有乙肝病毒S2[8]抗原表位的重组嵌合蛋白rVP6F/S2 [8],携带有乙肝病毒SI [93]抗原表位的重组嵌合蛋白rVP6F/Sl [93],能与HBsAb阳性的乙型肝炎患者的血清抗体发生特异性免疫反应。携带有乙肝病毒C19抗原表位的重组嵌合蛋白rVP6F/C19,携带有乙肝病毒C117抗原表位的重组嵌合蛋白rVP6F/C117,能与HBcAb阳性的乙型肝炎患者的血清抗体发生特异性免疫反应。同时携带乙肝病毒S82,C19,S125,S2[8],S1[93]和C117抗原表位的重组蛋白rVP6F⑥H,能与抗轮状病毒全病毒抗体发生特异性免疫反应,能与抗轮状病毒VP6蛋白抗体发生特异性免疫反应,能与HBsAb阳性的乙型肝炎患者的血清抗体发生特异性免疫反应,能与HBcAb阳性的乙型肝炎患者的血清抗体发生特异性免疫反应,不能与抗重组轮状病毒NSP2蛋白豚鼠血清抗体发生特异性免疫反应。用作阴性对照的重组轮状病毒NSP2蛋白只能与抗重组轮状病毒NSP2蛋白豚鼠血清抗体发生特异性免疫反应。用作阴性对照的牛血清白蛋白,不能与上述所有检测抗体发生特异性免疫反应。结论上述所有的重组嵌合蛋白均具有载体蛋白和所携带的抗原表位特异的抗原反应性。序列表
携带有乙肝病毒S82抗原表位的重组嵌合蛋白的氨基酸序列
Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp Lys He ValGlu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu He Gln Gln Phe Asn Gln Met He IleThr Met Asn Gly Asn Glu Phe Gln Thr Gly Gly He Gly Asn Leu Pro Thr Arg Asn TrpSer Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val GluThr Ala Arg Asn Thr He Asp Tyr Phe Val Asp Phe Val Asp Asn Val Cys Met Asp GluMet Val Arg Glu Ser Gln Arg Asn Gly He Ala Pro Gln Ser Glu Ser Leu Arg Lys LeuSer Gly He Lys Phe Lys Arg He Asn Phe Asp Asn Ser Ser Glu Tyr He Glu Asn TrpAsn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro Asn He Phe ProTyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Ala His Glu Leu Phe Leu Phe IleLeu Leu Leu Cys Leu Glu Leu Met Gly Thr Met Trp Leu Asn Ala Gly Ser Glu He GlnVal Ala Gly Phe Asp Tyr Ser Asn He Gln Gln Phe Glu His He Val Gln Leu Arg ArgVal Leu Thr Thr Ala Thr He Thr Leu Leu Pro Asp Ala Glu Arg Phe Ser Phe Pro ArgVal He Asn Ser Ala Asp Gly Thr Thr Trp Tyr Phe Asn Pro Val He Leu Arg Pro AsnAsn Val Glu Val Glu Phe Leu Leu Asn Gly Gln Ile He Asn Thr Tyr Gln Ala Pro ArgPhe Gly Thr He Val Ala Arg Asn Phe Asp Thr He Arg Leu Ser Phe Gln Leu Met ArgPro Arg Thr Pro Ser Val Ala Ala Leu Glu His His Ala Thr Val Gly Leu Thr Leu ArgHe Glu Ser Ala He Cys Glu Ser Val Leu Ala Asp Ala Ser Glu Thr Met Leu Ala AsnVal Thr Ser Val Arg Gln Glu Tyr Ala He Pro Val Gly Pro Val Phe Pro Pro Gly MetAsn Trp Thr Asp Leu He Thr Asn Tyr Ser Pro Ser Arg Glu Asp Asn Leu Gln Arg ValPhe Thr Val Ala Ser lie Arg Ser Met Leu Val Lys
抗原表位 S82 的氨基酸序列Phe Leu Phe lie Leu Leu Leu Cys Leu 携带有乙肝病毒C19抗原表位的重组嵌合蛋白的氨基酸序列 Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp Lys He ValGlu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu He Gln Gln Phe Asn Gln Met He IleThr Met Asn Gly Asn Glu Phe Gln Thr Gly Gly He Gly Asn Leu Pro Thr Arg Asn TrpSer Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val GluThr Ala Arg Asn Thr He Asp Tyr Phe Val Asp Phe Val Asp Asn Val Cys Met Asp GluMet Val Arg Glu Ser Gln Arg Asn Gly He Ala Pro Gln Ser Glu Ser Leu Arg Lys LeuSer Gly He Lys Phe Lys Arg He Asn Phe Asp Asn Ser Ser Glu Tyr He Glu Asn TrpAsn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro Asn He Phe ProTyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Ala His Glu Leu Met Gly Thr MetTrp Leu Asn Ala Gly Ser Glu He Gln Val Ala Gly Phe Asp Tyr Ser Asn Ser Phe LeuPro Ser Asp Phe Phe Pro Ser Val Arg Asp Ser Asn He Gln Gln Phe Glu His He ValGln Leu Arg Arg Val Leu Thr Thr Ala Thr He Thr Leu Leu Pro Asp Ala Glu Arg PheSer Phe Pro Arg Val He Asn Ser Ala Asp Gly Thr Thr Trp Tyr Phe Asn Pro Val IleLeu Arg Pro Asn Asn Val Glu Val Glu Phe Leu Leu Asn Gly Gln He He Asn Thr TyrGln Ala Pro Arg Phe Gly Thr He Val Ala Arg Asn Phe Asp Thr He Arg Leu Ser PheGln Leu Met Arg Pro Arg Thr Pro Ser Val Ala Ala Leu Glu His His Ala Thr Val GlyLeu Thr Leu Arg He Glu Ser Ala He Cys Glu Ser Val Leu Ala Asp Ala Ser Glu ThrMet Leu Ala Asn Val Thr Ser Val Arg Gln Glu Tyr Ala He Pro Val Gly Pro Val PhePro Pro Gly Met Asn Trp Thr Asp Leu He Thr Asn Tyr Ser Pro Ser Arg Glu Asp AsnLeu Gln Arg Val Phe Thr Val Ala Ser He Arg Ser Met Leu Val Lys抗原表位C19的氨基酸序列
Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp携带有乙肝病毒S125抗原表位的重组嵌合蛋白的氨基酸序列
Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp Lys He ValGlu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu He Gln Gln Phe Asn Gln Met He IleThr Met Asn Gly Asn Glu Phe Gln Thr Gly Gly He Gly Asn Leu Pro Thr Arg Asn TrpSer Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val GluThr Ala Arg Asn Thr He Asp Tyr Phe Val Asp Phe Val Asp Asn Val Cys Met Asp GluMet Val Arg Glu Ser Gln Arg Asn Gly He Ala Pro Gln Ser Glu Ser Leu Arg Lys LeuSer Gly He Lys Phe Lys Arg He Asn Phe Asp Asn Ser Ser Glu Tyr He Glu Asn TrpAsn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro Asn He Phe ProTyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Ala His Glu Leu Met Gly Thr MetTrp Leu Asn Ala Gly Ser Glu He Gln Val Ala Gly Phe Asp Tyr Ser Asn lie Gln GlnPhe Glu His He Val Gln Leu Arg Arg Val Leu Thr Thr Ala Thr lie Thr Leu Leu ProAsp Ala Glu Arg Phe Ser Phe Pro Arg Val lie Asn Ser Ala Asp Gly Thr Thr Pro AlaGln Gly Asn Ser Met Phe Pro Ser Cys Cys Cys Thr Lys Pro Thr Asp Gly Thr Thr TrpTyr Phe Asn Pro Val He Leu Arg Pro Asn Asn Val Glu Val Glu Phe Leu Leu Asn GlyGln He He Asn Thr Tyr Gln Ala Pro Arg Phe Gly Thr lie Val Ala Arg Asn Phe AspThr He Arg Leu Ser Phe Gln Leu Met Arg Pro Arg Thr Pro Ser Val Ala Ala Leu GluHis His Ala Thr Val Gly Leu Thr Leu Arg He Glu Ser Ala lie Cys Glu Ser Val LeuAla Asp Ala Ser Glu Thr Met Leu Ala Asn Val Thr Ser Val Arg Gln Glu Tyr Ala liePro Val Gly Pro Val Phe Pro Pro Gly Met Asn Trp Thr Asp Leu lie Thr Asn Tyr SerPro Ser Arg Glu Asp Asn Leu Gln Arg Val Phe Thr Val Ala Ser lie Arg Ser Met LeuVal Lys
抗原表位S125的氨基酸序列
Thr Thr Pro Ala Gln Gly Asn Ser Met Phe Pro Ser Cys Cys Cys Thr Lys Pro ThrAsp Gly
携带有乙肝病毒S2[8]抗原表位的重组嵌合蛋白的氨基酸序列
Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp Lys He ValGlu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu He Gln Gln Phe Asn Gln Met He IleThr Met Asn Gly Asn Glu Phe Gln Thr Gly Gly He Gly Asn Leu Pro Thr Arg Asn TrpSer Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val GluThr Ala Arg Asn Thr He Asp Tyr Phe Val Asp Phe Val Asp Asn Val Cys Met Asp GluMet Val Arg Glu Ser Gln Arg Asn Gly He Ala Pro Gln Ser Glu Ser Leu Arg Lys LeuSer Gly He Lys Phe Lys Arg He Asn Phe Asp Asn Ser Ser Glu Tyr He Glu Asn TrpAsn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro Asn He Phe ProTyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Ala His Glu Leu Met Gly Thr MetTrp Leu Asn Ala Gly Ser Glu He Gln Val Ala Gly Phe Asp Tyr Ser Asn He Gln GlnPhe Glu His He Val Gln Leu Arg Arg Val Leu Thr Thr Ala Thr He Thr Leu Leu ProAsp Ala Glu Arg Phe Ser Phe Pro Arg Val He Asn Ser Ala Asp Gly Thr Thr Trp TyrPhe Asn Pro Val He Leu Arg Pro Asn Asn Val Glu Val Glu Phe Leu Leu Asn Gly GlnIle He Asn Thr Tyr Gln Ala Pro Arg Phe His Gln Ala Leu Gln Asp Pro Arg Val ArgGly Leu Tyr Phe Pro Ala Gly Pro Arg Phe Gly Thr He Val Ala Arg Asn Phe Asp ThrHe Arg Leu Ser Phe Gln Leu Met Arg Pro Arg Thr Pro Ser Val Ala Ala Leu Glu HisHis Ala Thr Val Gly Leu Thr Leu Arg He Glu Ser Ala He Cys Glu Ser Val Leu AlaAsp Ala Ser Glu Thr Met Leu Ala Asn Val Thr Ser Val Arg Gln Glu Tyr Ala He ProVal Gly Pro Val Phe Pro Pro Gly Met Asn Trp Thr Asp Leu He Thr Asn Tyr Ser ProSer Arg Glu Asp Asn Leu Gln Arg Val Phe Thr Val Ala Ser He Arg Ser Met Leu ValLys
抗原表位S2[8]的氨基酸序列
Pro Arg Phe His Gln Ala Leu Gln Asp Pro Arg Val Arg Gly Leu Tyr Phe Pro AlaGly
携带有乙肝病毒Sl[93]抗原表位的重组嵌合蛋白的氨基酸序列
Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp Lys He ValGlu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu He Gln Gln Phe Asn Gln Met He IleThr Met Asn Gly Asn Glu Phe Gln Thr Gly Gly He Gly Asn Leu Pro Thr Arg Asn TrpSer Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val GluThr Ala Arg Asn Thr He Asp Tyr Phe Val Asp Phe Val Asp Asn Val Cys Met Asp GluMet Val Arg Glu Ser Gln Arg Asn Gly He Ala Pro Gln Ser Glu Ser Leu Arg Lys LeuSer Gly He Lys Phe Lys Arg He Asn Phe Asp Asn Ser Ser Glu Tyr He Glu Asn TrpAsn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro Asn He Phe ProTyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Ala His Glu Leu Met Gly Thr MetTrp Leu Asn Ala Gly Ser Glu He Gln Val Ala Gly Phe Asp T yr Ser Asn He Gln GlnPhe Glu His He Val Gln Leu Arg Arg Val Leu Thr Thr Ala Thr He Thr Leu Leu ProAsp Ala Glu Arg Phe Ser Phe Pro Arg Val He Asn Ser Ala Asp Gly Thr Thr Trp TyrPhe Asn Pro Val He Leu Arg Pro Asn Asn Val Glu Val Glu Phe Leu Leu Asn Gly GlnIle He Asn Thr Tyr Gln Ala Pro Arg Phe Gly Thr He Val Ala Arg Asn Phe Asp ThrHe Arg Leu Ser Phe Gln Leu Met Arg Pro Arg Pro Pro Pro Ala Ser Thr Asn Arg GlnSer Gly Arg Gln Pro Arg Thr Pro Ser Val Ala Ala Leu Glu His His Ala Thr Val GlyLeu Thr Leu Arg He Glu Ser Ala He Cys Glu Ser Val Leu Ala Asp Ala Ser Glu ThrMet Leu Ala Asn Val Thr Ser Val Arg Gln Glu Tyr Ala He Pro Val Gly Pro Val PhePro Pro Gly Met Asn Trp Thr Asp Leu He Thr Asn Tyr Ser Pro Ser Arg Glu Asp AsnLeu Gln Arg Val Phe Thr Val Ala Ser He Arg Ser Met Leu Val Lys
抗原表位SI [93]的氨基酸序列
Pro Pro Pro Ala Ser Thr Asn Arg Gln Ser Gly Arg Gln0携带有乙肝病毒Cl 17抗原表位的重组嵌合蛋白的氨基酸序列
Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp Lys He ValGlu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu He Gln Gln Phe Asn Gln Met He IleThr Met Asn Gly Asn Glu Phe Gln Thr Gly Gly He Gly Asn Leu Pro Thr Arg Asn TrpSer Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val GluThr Ala Arg Asn Thr He Asp Tyr Phe Val Asp Phe Val Asp Asn Val Cys Met Asp GluMet Val Arg Glu Ser Gln Arg Asn Gly He Ala Pro Gln Ser Glu Ser Leu Arg Lys LeuSer Gly He Lys Phe Lys Arg He Asn Phe Asp Asn Ser Ser Glu Tyr He Glu Asn TrpAsn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro Asn He Phe ProTyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Ala His Glu Leu Met Gly Thr MetTrp Leu Asn Ala Gly Ser Glu He Gln Val Ala Gly Phe Asp Tyr Ser Asn He Gln GlnPhe Glu His He Val Gln Leu Arg Arg Val Leu Thr Thr Ala Thr He Thr Leu Leu ProAsp Ala Glu Arg Phe Ser Phe Pro Arg Val He Asn Ser Ala Asp Gly Thr Thr Trp TyrPhe Asn Pro Val He Leu Arg Pro Asn Asn Val Glu Val Glu Phe Leu Leu Asn Gly GlnIle He Asn Thr Tyr Gln Ala Pro Arg Phe Gly Thr He Val Ala Arg Asn Phe Asp ThrIle Arg Leu Ser Phe Gln Leu Met Arg Pro Arg Thr Pro Ser Val Ala Ala Leu Glu TyrLeu Val Ser Phe Gly Val Trp He Arg Thr Pro Pro Ala Tyr Arg Pro Pro Asn Ala ProHe Leu Glu His His Ala Thr Val Gly Leu Thr Leu Arg lie Glu Ser Ala lie Cys GluSer Val Leu Ala Asp Ala Ser Glu Thr Met Leu Ala Asn Val Thr Ser Val Arg Gln GluTyr Ala He Pro Val Gly Pro Val Phe Pro Pro Gly Met Asn Trp Thr Asp Leu lie ThrAsn Tyr Ser Pro Ser Arg Glu Asp Asn Leu Gln Arg Val Phe Thr Val Ala Ser lie ArgSer Met Leu Val Lys
抗原表位Cl 17的氨基酸序列
Tyr Leu Val Ser Phe Gly Val Trp He Arg Thr Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro lie
同时携带乙肝病毒S82,C19,S125,S2[8],SI [93]和C117抗原表位的重组蛋白的氨基酸序列
Met Asp Val Leu Tyr Ser Leu Ser Lys Thr Leu Lys Asp Ala Arg Asp Lys He ValGlu Gly Thr Leu Tyr Ser Asn Val Ser Asp Leu He Gln Gln Phe Asn Gln Met He IleThr Met Asn Gly Asn Glu Phe Gln Thr Gly Gly He Gly Asn Leu Pro Thr Arg Asn TrpSer Phe Asp Phe Gly Leu Leu Gly Thr Thr Leu Leu Asn Leu Asp Ala Asn Tyr Val GluThr Ala Arg Asn Thr He Asp Tyr Phe Val Asp Phe Val Asp Asn Val Cys Met Asp GluMet Val Arg Glu Ser Gln Arg Asn Gly He Ala Pro Gln Ser Glu Ser Leu Arg Lys LeuSer Gly He Lys Phe Lys Arg He Asn Phe Asp Asn Ser Ser Glu Tyr He Glu Asn TrpAsn Leu Gln Asn Arg Arg Gln Arg Thr Gly Phe Thr Phe His Lys Pro Asn He Phe ProTyr Ser Ala Ser Phe Thr Leu Asn Arg Ser Gln Pro Ala His Glu Leu Phe Leu Phe IleLeu Leu Leu Cys Leu Glu Leu Met Gly Thr Met Trp Leu Asn Ala Gly Ser Glu He GlnVal Ala Gly Phe Asp Tyr Ser Asn Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val ArgAsp Ser Asn He Gln Gln Phe Glu His He Val Gln Leu Arg Arg Val Leu Thr Thr AlaThr He Thr Leu Leu Pro Asp Ala Glu Arg Phe Ser Phe Pro Arg Val He Asn Ser AlaAsp Gly Thr Thr Pro Ala Gln Gly Asn Ser Met Phe Pro Ser Cys Cys Cys Thr Lys ProThr Asp Gly Thr Thr Trp Tyr Phe Asn Pro Val He Leu Arg Pro Asn Asn Val Glu ValGlu Phe Leu Leu Asn Gly Gln He He Asn Thr Tyr Gln Ala Pro Arg Phe His Gln AlaLeu Gln Asp Pro Arg Val Arg Gly Leu Tyr Phe Pro Ala Gly Pro Arg Phe Gly Thr IleVal Ala Arg Asn Phe Asp Thr He Arg Leu Ser Phe Gln Leu Met Arg Pro Arg Pro ProPro Ala Ser Thr Asn Arg Gln Ser Gly Arg Gln Pro Arg Thr Pro Ser Val Ala Ala LeuGlu Tyr Leu Val Ser Phe Gly Val Trp He Arg Thr Pro Pro Ala Tyr Arg Pro Pro AsnAla Pro He Leu Glu His His Ala Thr Val Gly Leu Thr Leu Arg He Glu Ser Ala IleCys Glu Ser Val Leu Ala Asp Ala Ser Glu Thr Met Leu Ala Asn Val Thr Ser Val ArgGln Glu Tyr Ala He Pro Val Gly Pro Val Phe Pro Pro Gly Met Asn Trp Thr Asp LeuHe Thr Asn Tyr Ser Pro Ser Arg Glu Asp Asn Leu Gln Arg Val Phe Thr Val Ala SerHe Arg Ser Met Leu Val Lys引物
S82F CTTCCTCTTCATCCTGCTGCTATGCCTGGAGCTS82R CCAGGCATAGCAGCAGGATGAAGAGGAAGAGCT
C19F CGAATCATTTTTGCCTTCTGACTTCTTTCCTTCCGTCCGGGATTTC19R CGAAATCCCGGACGGAAGGAAAGAAGTCAGAAGGCAAAAATGATTS125F CACTCCTGCTCAAGGCAACTCTATGTTTCCCTCATGTTGCTGTACAAAACCTACGGATGGTACS125R CATCCGTAGGTTTTGTACAGCAACATGAGGGAAACATAGAGTTGCCTTGAGCAGGAGTGGTACS2[8] F CTAGGTTCCACCAAGCTCTGCAAGATCCCAGAGTCAGGGGCCTGTATTTTCCTGCTGGTCS2[8] R CTAGGACCAGCAGGAAAATACAGGCCCCTGACTCTGGGATCTTGCAGAGCTTGGTGGAACSI[93]F GGCCTCCTCCTGCCTCCACCAATCGGCAGTCAGGAAGGCAGCCGCSI[93] R GGCTGCCTTCCTGACTGCCGATTGGTGGAGGCAGGAGGAGGCCGCC117F TCGAGTATTTGGTCTCTTTCGGAGTGTGGATTCGCACTCCACCAGCTTATAGACCACCAAATGCCCCTATCC
C117R TCGAGGATAGGGGCATTTGGTGGTCTATAAGCTGGTGGAGTGCGAATCCACACTCCGAAAGAGACCA AATAC
携带有 Sac I 位点、BspT104 I 位点、Kpn I (ggtacc)位点、Bin I (ccgcgg)位点、Sac
II(ccrcrr)位点及Xho I (ctcRaR)位点的VP6载体蛋白编码基因的核苷酸序列:
I atggatgttt tgtattcatt atcaaaaact cttaaggatg ctagagacaa 51 aattgtcgaa ggcactttat actctaatgt tagtgatcta attcaacaat 101 ttaatcaaat gataattact atgaatggaa atgaatttca aactggagga 151 attggtaatc taccaaccag aaattggagt tttgattttg gtttacttgg 201 aactacgctt ttgaatttag atgccaatta tgttgaaact gcgcgtaaca 251 caattgatta ttttgttgat tttgtagata acgtatgtat ggatgagatg 301 gttagagaat cacaaagaaa cggaattgca ccgcagtcag aatcacttag 351 aaaactatca gggattaagt ttaaaagaat aaattttgac aattcgtcgg 401 aatacataga aaactggaac ttgcaaaata gaagacaaag aactggtttt 451 acatttcata aaccaaacat ctttccatat tcagcttcat ttacgttaaa 501 tagatcacaa cctgcgcatg_agctcatggg tacaatgtgg ttgaatgcag 551 gttcagagat tcaagttgct ggatttgatt attcRaacat acagcaattt 601 gagcatatag ttcagctccg tagggtgtta acgacggcta caataactct 651 tttaccagat gctgaaaggt ttagtttccc tagagtaatt aattcagctg 701 atRRtaccac atggtatttt aatccagtaa tacttagacc gaataatgtc 751 gaagtagaat ttctattgaa tggacagata ataaatactt atcaggcacc 801 taggtttggt acaattgta
查看更多专利详情

下载专利文献

下载专利